Video
Review of Updated Efficacy and Safety Data from the EMPOWER-CSCC-1 Trial
Dr Hanna comments on updated efficacy and safety data of the EMPOWER-CSCC-1 trial that was recently discussed at the annual ESMO and ASCO 2022 meetings.
EP: 1.Overview of Cutaneous Squamous Cell Carcinoma (cSCC)
EP: 2.Treatment Options for Patients with cSCC in the Neoadjuvant Setting
EP: 3.Current Treatment Options for Patients with Advanced Cutaneous Squamous Cell Carcinoma (cSCC)
Now Viewing
EP: 4.Review of Updated Efficacy and Safety Data from the EMPOWER-CSCC-1 Trial
EP: 5.Role of Cemiplimab in the Neoadjuvant Setting for Patients with cSCC
EP: 6.Real-World Data of Cemiplimab in Patients with Advanced cSCC
EP: 7.Investigational Agents for the Treatment of Advanced cSCC
EP: 8.An Overview of Advanced Basal Cell Carcinoma (BCC) and Currently Available Treatment Options
EP: 9.Future Perspectives in cSCC
EP: 10.Treatment Options for Patients with Advanced Basal Cell Carcinoma (BCC)
EP: 11.Looking Ahead: Unmet Needs for the Treatment of BCC
Related Videos
Related Content
Published: July 25th 2024 | Updated: July 25th 2024
FDA Accepts Resubmission of BLA for Cosibelimab in Locally Advanced or Metastatic CSCC
